With continued support from Bay partners, the third edition of the Marina Bay Precinct Partnership will feature nautical-themed festivities across two months with Disney Cruise Line-themed photo spots and additional special privileges for UOB customers at the Bay area. Marina Bay precinct partners UOB, Marina Bay Sands, and Singapore Tourism Board (STB), together with Disney […]

With continued support from Bay partners, the third edition of the Marina Bay Precinct Partnership will feature nautical-themed festivities across two months with Disney Cruise Line-themed photo spots and additional special privileges for UOB customers at the Bay area. Marina Bay precinct partners UOB, Marina Bay Sands, and Singapore Tourism Board (STB), together with Disney

Revizto, the leading collaboration platform for the Architecture, Engineering, Construction & Operations (AECO) is proud to announce it has officially achieved the Secure by Design (SbD) First Line Assessment accreditation from the UK Defence Infrastructure Organization (DIO). This milestone confirms that Revizto’s security posture and risk management controls meet the rigorous standards required to handle

(TSX:TECK.A),(TSX:TECK.B),(TSX:TECK-A),(TSX:TECK-B),(NYSE:TECK), VANCOUVER, British Columbia, Feb. 19, 2026 (GLOBE NEWSWIRE) — Teck Resources Limited (TSX: TECK.A and TECK.B, NYSE: TECK) (Teck) today announced its unaudited fourth quarter results for 2025. “Teck closed out 2025 with strong momentum, delivering robust Q4 financial performance underpinned by significantly higher copper prices and operating performance in line with plan,” said

Teck Reports Unaudited Fourth Quarter Results for 2025 Strong momentum built in Q4 and progressing merger to create global critical minerals champion GlobeNewswire February 19, 2026 VANCOUVER, British Columbia, Feb. 19, 2026 (GLOBE NEWSWIRE) — Teck Resources Limited (TSX: TECK.A and TECK.B, NYSE: TECK) (Teck) today announced its unaudited fourth quarter results for 2025. “Teck

(BX Swiss AG:BIOV.SW), Data from Phase 2a study demonstrated the first clinical proof of concept for alpibectir in combination with ethionamide (AlpE) in the treatment of patients with tuberculosis. The results, published in the prestigious New England Journal of Medicine, underscore the significant potential of AlpE to shape the future of TB treatment. BASEL, Switzerland,

(Copenhagen:ZEAL), Company announcement – No. 1 / 2026 Zealand Pharma Announces Financial Results for the Full Year 2025 2025 marked a quantum leap for Zealand Pharma, with a transformative partnership for petrelintide, strong clinical progress, and organizational readiness, setting the stage for catalyst-rich and defining 2026 Entered a historic and transformative collaboration and license agreement

(Paris:NEX), 2025 Full-Year results Excellent financial performance reflecting the strengths of Nexans' business model Exceptional level of organic growth at +8.3% in 2025 Strong Adjusted EBITDA margin increase at 11.9% of standard sales Portfolio rotation – Exclusive negotiations entered into for the sale of Autoelectric Solid balance sheet enabling to step-up M&A activity Entering 2026

(Euronext Amsterdam:AGN),(LSE:50OR), Schiphol, February 19, 2026 – Please click here to access all 2H 2025 results related documents 2H 2025 Financial highlights Net result of EUR 375 million, a decrease compared with EUR 741 million in the second half of 2024, as growth in the operating result is offset by non-operating items and other charges.

(Paris:VLA),(Paris:VLAP), Total Revenues of EUR174.7 million in line with guidance, including EUR157.9 million in product sales Strong year-end cash position of EUR109.7 million, with enhanced financial flexibility following successful debt refinancing 2026 to be a potentially transformational year with Phase 3 Lyme disease data expected in the first half of the year Chief Executive Officer's